Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Gail Model (Relative Risk)

The Gail Model (Breast Cancer Risk Assessment Tool) estimates a woman's risk of developing invasive breast cancer over the next 5 years and in her lifetime.

Evidence-based context for fast calculator use

Purpose:
Gail Model estimates 5-year and lifetime relative risk of invasive breast cancer to identify candidates for chemoprevention with tamoxifen.
Population:
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
Factors:
Age at Menarche, Age at First Live Birth, First-degree relatives with breast cancer, History of Breast Biopsies, History of Atypical Hyperplasia?
Reference:
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
HomeGail Model (Relative Risk)
Pin your most used calculators here by clicking the star in the dropdown.

Gail Model (Relative Risk)

Clinical Context & Background

The Gail Model (Breast Cancer Risk Assessment Tool) estimates a woman's risk of developing invasive breast cancer over the next 5 years and in her lifetime. This calculator computes the Relative Risk (RR) score based on medical history, which is then compared to population averages.
Primary Source EvidenceGail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
Formula Logic
Relative Risk calculated from Age at Menarche, First Birth, Biopsy Hx, and Family Hx.

Reference Data

Relative Risk (RR)Interpretation
1.0Average Risk
> 1.0Higher than average risk
≥ 1.67High Risk (Consider chemoprevention e.g. Tamoxifen/Raloxifene)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Gail Model (Relative Risk) when gail Model estimates 5-year and lifetime relative risk of invasive breast cancer to identify candidates for chemoprevention with tamoxifen.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 1.0 through ≥ 1.67.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify Age at Menarche, Age at First Live Birth, First-degree relatives with breast cancer, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

PREDICT Breast (Prognostic Index)CTS5 Late Breast Cancer RecurrenceOncotype DX Recurrence Score Calculator — Breast Cancer Genomic Risk

Frequently Asked Questions

When should Gail Model (Relative Risk) be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can Gail Model (Relative Risk) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.